|
| Press Releases |
|
 |
|
| Friday, September 4, 2020 |
|
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
| Thursday, July 23, 2020 |
|
|
아방스 클리니컬, 아토사 테라퓨틱스의 두 번째 코로나19 치료제 개발 프로그램인 비강 분무용 치료제 AT-301 임상 연구 계약 |
| 호주의 앞서가는 바이오텍 임상시험수탁기관(CRO)이자 프로스트 앤 설리번(Frost & Sullivan)이 ‘2020 아시아 태평양 CRO 시장 선두기관’으로 선정한 아방스 클리니컬(Avance Clinical)은 아토사 테라퓨틱스(Atossa Therapeutics)의 비강 분무용 전매 신약 후보인 AT-301 관련 임상 연구 시행 계약을 맺었다. 아방스 클리니컬은 아토사 테라퓨틱스의 전매 약제인 엔독시펜(Endoxifen) 임상 연구를 몇 차례 성공적으로 완료한 바 있다. more info >> |
|
|
Avance Clinical簽約展開Atossa Therapeutics AT-301鼻噴霧劑臨床研究，這是Atossa的第二個新冠肺炎治療開發項目 |
| 澳大利亞領先的生物技術CRO和Frost & Sullivan 2020年亞太區CRO市場領導獎獲得者Avance Clinical正式簽約，對Atossa Therapeutics的專利候選藥物AT-301進行臨床研究，該藥物將通過鼻噴霧劑給藥。 Avance已經成功地完成了Atossa專利Endoxifen的多項臨床研究。 more info >> |
|
|
Avance Clinical签约展开Atossa Therapeutics AT-301鼻喷雾剂临床研究，这是Atossa的第二个新冠肺炎治疗开发项目 |
| 澳大利亚领先的生物技术CRO和Frost & Sullivan 2020年亚太区CRO市场领导奖获得者Avance Clinical正式签约，对Atossa Therapeutics的专利候选药物AT-301进行临床研究，该药物将通过鼻喷雾剂给药。Avance已经成功地完成了Atossa专利Endoxifen的多项临床研究。 more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
| Thursday, July 9, 2020 |
|
|
아방스 클리니컬, 프로스트 앤 설리번의 “2020 아시아태평양 CRO 시장 리더십 어워즈” 수상 |
| 호주 바이오테크 분야 임상시험수탁기관(CRO) 중 선두를 달리고 있는 아방스 클리니컬(Avance Clinical)은 지난 밤 프로스트 앤 설리번 (Frost & Sullivan) 주체로 열린 2020 아시아태평양 CRO 시장 리더십 어워즈 온라인 시상식에서 수상했다. more info >> |
|
|
Avance Clinical榮獲Frost & Sullivan 2020亞太CRO市場領導力獎 |
| Avance Clinical在全球遠程線上獎頒獎典禮上榮獲由Frost & Sullivan 頒發的久負盛名的 2020亞太CRO市場領導力獎，其是澳大利亞在CRO 生物技術方面領先的公司。 more info >> |
|
|
Avance Clinical荣获Frost & Sullivan“2020亚太CRO市场领导力奖” |
| Avance Clinical在全球远程线上奖颁奖典礼上荣获由Frost & Sullivan 颁发的久负盛名的“2020亚太CRO市场领导力奖”，其是澳大利亚在CRO 生物技术方面领先的公司。 more info >> |
|
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
| The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
| Wednesday, June 10, 2020 |
|
|
바이오 디지털2020 참가한 아방스 클리니컬, “트라이얼트로브 데이터 통해 호주의 우호적 기업 환경 드러나” |
| 호주의 앞서가는 임상시험수탁기관(CRO)인 아방스 클리니컬(Avance Clinical)은 오늘 열린 바이오 디지털(BIO Digital) 행사에 참가해 현재 호주에서 계획 중이거나 진행 중인 임상시험 건수가 2,413건에 달한다고 밝혔다. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
侨雄国际宣布委任段玉聪院士为人工智能实验室首席科学家
Nov 5, 2024 19:25 HKT/SGT
|
|
|
华邦科技正式更名为「亨利加集团有限公司」
Nov 5, 2024 19:15 HKT/SGT
|
|
|
華邦科技正式更名為「亨利加集團有限公司」
Nov 5, 2024 19:11 HKT/SGT
|
|
|
僑雄國際宣佈委任段玉聰院士為人工智能實驗室首席科學家
Nov 5, 2024 19:00 HKT/SGT
|
|
|
ALMAC to open mid-November
Nov 5, 2024 18:46 HKT/SGT
|
|
|
Champion REIT Recognised as 'GRESB Global Listed Sector Leader'
Nov 5, 2024 18:11 HKT/SGT
|
|
|
富士通、東証の株式売買システム「arrowhead4.0」を運用開始
Nov 5, 2024 18:00: JST
|
|
|
冠君产业信托获GRESB评为「全球业界领导者（上市企业）」
Nov 5, 2024 17:41 HKT/SGT
|
|
|
冠君產業信託獲GRESB評為「全球業界領導者（上市企業）」
Nov 5, 2024 17:14 HKT/SGT
|
|
|
Victory and world title for TOYOTA GAZOO Racing
Nov 5, 2024 17:59 JST
|
|
|
Tokyo Stock Exchange and Fujitsu announce renewal of cash equity trading system 'arrowhead4.0'
Nov 5, 2024 17:13 JST
|
|
|
Mitsubishi Heavy Industries Continues Order Intake, Revenue, and Profit Growth in Strong First Half, Raises Full-Year Order Intake Guidance
Nov 5, 2024 14:37 JST
|
|
|
Interroyal Engineering PCL (SET: IROYAL) Posts Strong Showing on First Trading Day
Nov 5, 2024 13:00 HKT/SGT
|
|
|
華泰證券入圍「跨境理財通」試點 服務大灣區多元化財富管理需求
Nov 5, 2024 11:50 HKT/SGT
|
|
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 5, 2024 11:35 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
